IRLAB: Positive feedback from EMA regarding Mesdopetam phase III program - Redeye
Bildkälla: Stockfoto

IRLAB: Positive feedback from EMA regarding Mesdopetam phase III program - Redeye

Redeye is positive to the news that EMA has returned with positive feedback to IRLAB’s phase III plans for Mesdopetam, and we give an initial take.

Redeye is positive to the news that EMA has returned with positive feedback to IRLAB’s phase III plans for Mesdopetam, and we give an initial take.
Börsvärldens nyhetsbrev
ANNONSER